Report Overview:
The global key manufacturers of Allergic Conjunctivitis Drugs include Bausch Health Companies Inc, Merck & Co. Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Bayer AG, Novartis AG, Endo International plc, Lupin and Cipla Inc, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Allergic conjunctivitis is a type of eye disorder that is characterized by inflammation in the conjunctiva because of allergens, pollen grain, dust mites, cosmetics, chemicals and perfumes. It is also commonly known as pink eye that leads to swell the outer membrane of eyeball. It does not cause any other serious health problems if diagnosed and treated at early stages. The common symptoms include gritty feelings in the eye, abnormal tears amount, itchiness in eyes, thick discharges that form up in the eye during night time and pink or red colour toned eyes.
Market Value:
The global Allergic Conjunctivitis Drugs market size was valued at US$ 2.89 billion in 2024 and is projected to reach US$ 3.78 billion by 2030, at a CAGR of 4.6% during the forecast period 2024-2030. CAGR of 4.6%
(2022 – 2029)
